natgillin/translations-raw huggingface dataset:
Inducers of P-gp (St. John’s wort, rifampicin) might therefore decrease the bioavailability of Tekturna.
Zato lahko induktorji P-gp (šentjanževka, rifampin) zmanjšajo biološko uporabnost zdravila Tekturna.
inducers, DTG/ABC/3TC FDC is not
Antikonvulzivi
induction and
Indukcija
induction by
C8 z
induction by
Indukcija
induction by
Mehanizem: Indukcija CYP2C19 z
induction by
↓ paritaprevir
Induction chemotherapy followed by chemoradiotherapy (TAX 324)
Indukcijska kemoterapija in nato kemoradioterapija (TAX 324)
Induction chemotherapy followed by chemoradiotherapy (TAX 324)
Indukcijska kemoterapija in nato radioterapija (TAX 323)
Induction chemotherapy followed by chemoradiotherapy (TAX 324)
Predhodna kemoterapija bi morala vključevati antraciklin.
Induction chemotherapy followed by chemoradiotherapy (TAX324)
Indukcijska kemoterapija in nato kemoradioterapija (TAX324)
Induction chemotherapy followed by chemoradiotherapy (TAX324)
Indukcijska kemoterapija in nato radioterapija (TAX323)
Induction chemotherapy followed by radiotherapy (TAX 323)
Indukcijska kemoterapija in nato obsevanje (TAX 323)
Induction chemotherapy followed by radiotherapy (TAX 323)
Indukcijska kemoterapija in nato radioterapija (TAX 323)
Induction chemotherapy followed by radiotherapy (TAX 323)
Indukcijska kemoterapija in nato radioterapija (TAX323)
Induction chemotherapy followed by radiotherapy (TAX 323).
Indukcijska kemoterapija in nato radioterapija (TAX 323)
Induction chemotherapy followed by radiotherapy (TAX323)
Indukcijska kemoterapija in nato obsevanje (TAX323)
Induction chemotherapy followed by radiotherapy (TAX323)
Indukcijska kemoterapija in nato radioterapija (TAX 323)
Induction chemotherapy followed by radiotherapy (TAX323)
Indukcijska kemoterapija in nato radioterapija (TAX323)
Induction chemotherapy followed by radiotherapy(TAX323).
Indukcijska kemoterapija in nato radioterapija (TAX323)
induction of bupropion
Fluvastatin ali pravastatin
Induction of clinical remission (defined as CDAI < 150) was evaluated in two studies, CD Study I (CLASSIC I) and CD Study II (GAIN).
Indukcija klinične remisije (definirane kot CDAI < 150) je bila ovrednotena v dveh študijah, študija Crohnove bolezni I (CLASSIC I) in študija Crohnove bolezni II (GAIN).
Induction of clinical remission (defined as CDAI < 150) was evaluated in two studies, CD study I (CLASSIC I) and CD Study II (GAIN).
Indukcijo klinične remisije (opredeljene kot CDAI < 150) so ocenili v dveh študijah, študiji pri Crohnovi bolezni I (CLASSIC I) in študiji pri Crohnovi bolezni II (GAIN).
Induction of clinical remission (defined as CDAI < 150) was evaluated in two studies, CD Study I (CLASSIC I) and CD Study II (GAIN).
V študiji HS-I (PIONEER I) je bilo ocenjenih 307 v dveh obdobjih zdravljenja.
Induction of CYP 1A2 by tipranavir/r
Tipranavir/r inducira CYP 1A2.
Induction of CYP 2C19 by
Tipranavir/r inducira CYP 2C19.
Induction of CYP 2C19 by tipranavir/r
Tipranavir/r inducira CYP 2C19.
Induction of CYP1A2
Povečano delovanje CYP1A2
Induction of CYP1A2:
Indukcija CYP1A2
induction of CYP3A by
indukcija CYP3A z
Induction of dexmedetomidine in vitro was observed on CYP1A2, CYP2B6, CYP2C8, CYP2C9 and CYP3A4, and induction in vivo cannot be excluded.
Opazili so indukcijo deksmedetomidina in vitro na CYP1A2, CYP2B6, CYP2C8, CYP2C9 in CYP3A4, zato ne moremo izključiti indukcije in vivo.
Induction of glucose intolerance or diabetes mellitus.
Pojav intolerance za glukozo ali sladkorne bolezni.
Induction of hepatic metabolism has not been observed in clinical studies.
V kliničnih študijah niso zasledili indukcije jetrnih encimov.
Induction of remission in Crohn’s disease
Indukcija remisije Crohnove bolezni
Induction of remission in Crohn’s disease may take up to 14 weeks in some patients.
Pri nekaterih bolnikih lahko indukcija remisije Crohnove bolezni traja do 14 tednov.
Induction of such tumours is consistent with pharmacology-related endocrine feedback alterations in gonadotropin levels caused by anti-estrogens in cycling animals.
Indukcija tovrstnih tumorjev je v skladu s farmakološko povezanimi spremembami endokrine povratne zanke pri ravneh gonadotropina, ki jih povzročajo anti-estrogeni pri živalih, ki imajo cikluse.
Induction therapy
indukcijsko zdravljenje
Induction therapy
konsolidacijsko zdravljenje
Induction therapy (de novo Ph+ ALL)
Indukcijsko zdravljenje (novo odkrita Ph+ ALL)
Induction therapy CP 1.2 g/m2 i.v. (3 h), day 1; daunorubicin 60 mg/m2 i.v. (1 h), days 1-3;
indukcijsko zdravljenje CP 1,2 g/m2 i.v. (3 ure), 1. dan;
Induction therapy I
Indukcijsko zdravljenje I
Induction therapy I
indukcijsko zdravljenje II
Induction therapy II
indukcijsko zdravljenje II
Induction therapy: 50 mg administered every 14 days for 2 doses (weeks 1 and 3).
Začetno zdravljenje: 50 mg vsakih 14 dni, 2 odmerka (1. in 3. teden).
Induction Transplant Regimens Graph
Diagram režima uvajanja pred transplantacijo
Induction Transplant Regimens Graph.
Diagram režima uvajanja pred transplantacijo
Induction treatment in fistulising active Crohn’s disease
Začetno zdravljenje pri aktivni Crohnovi bolezni s fistulami
Induction treatment in moderately to severely active Crohn’s disease
Začetno zdravljenje pri zmerno do močno aktivni Crohnovi bolezni
Induction- consolidation therapy
indukcijsko
Induction- consolidation therapy
indukcijsko- konsolidacijsko zdravljenje
Induction-consolidation therapy
indukcijsko- konsolidacijsko zdravljenje
Induction-consolidation therapy
indukcijsko-konsolidacijsko zdravljenje
Inductive effect of tipiracil on human CYP isoforms cannot be excluded.
Inducirajočega učinka tipiracila na humane izoforme citokroma ni mogoče izključiti.
Inductive effect of tipiracil on human CYP isoforms cannot be excluded.
Inducirajočega učinka tipiracila na humane izoforme CYP ni mogoče izključiti.
InductOs 4 mg pack contains:
mg pakiranje zdravila InductOs vsebuje:
InductOs contains bovine collagen, a protein obtained from cattle
Zdravilo Inductos vsebuje goveji kolagen, beljakovino, pridobljeno iz govedi
InductOs does not provide mechanical stability and should not be used to fill a void in the presence of compressive forces.
Zdravilo InductOs ne zagotavlja mehanske stabilnosti in ga zato ne smete uporabljati za zapolnitev praznine ob delovanju kompresivnih sil.
InductOs has no or negligible influence on the ability to drive and use machines.
Zdravilo InductOs nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
InductOs is prepared immediately prior to use.
Zdravilo InductOs se pripravlja neposredno pred uporabo.
InductOs is supplied to your doctor as a kit for implanting during surgery.
Zdravniku je zdravilo InductOs na voljo v obliki kompleta za vsaditev med operacijo.
Inductos is used in adults who have been treated for at least six months for back pain due to a damaged disc but have not had an operation. surgery to heal fractures (breaks) of the tibia (shin bone).
Zdravilo Inductos se uporablja pri odraslih, ki so bili vsaj šest mesecev zdravljeni zaradi bolečin v hrbtenici, ki jo povzroča poškodovana medvretenčna ploščica, a še niso bili operirani; pri kirurških posegih za zdravljenje zlomov golenice.
InductOs may be placed into a void (loosely packed), folded, rolled or wrapped, as the geometry of the fracture requires.
Glede na geometrijo zloma lahko z zdravilom InductOs bodisi (narahlo) zapolnite praznino ali pa ga zložite, zvijete ali ovijete.
InductOs must be prepared exactly in accordance with the directions for preparation (see section 6.6).
Zdravilo InductOs mora biti pripravljeno natančno v skladu z navodili za pripravo (glejte poglavje 6.6).
InductOs will not affect your ability to drive or operate machines.
Zdravilo InductOs ne bo vplivalo na vašo sposobnost vožnje in upravljanja s stroji.
induration
induracija,
Induration
zatrdlina
Induration and ecchymosis were very common reaction in toddlers but were less common in infants.
Induracija in ekhimoza sta bila zelo pogosta neželena učinka pri malčkih, vendar manj pogosta pri dojenčkih.
induration and warmth at the injection site, influenza like illness, malaise
zatrdelo in toplo mesto injiciranja, gripi podobna bolezen, splošno slabo počutje
Induration*
Indura- cija
Industrie straße 32-36, 23843 Bad Oldesloe, Germany
Industrie straße 32-36, 23843 Bad Oldesloe, Nemčija
Industriestrasse 67 A-1221 Vienna Austria
Industriestrasse 67 A-1221 Dunaj, Avstrija
Industriestrasse 67 A-1221 Vienna Austria
Industriestrasse 67 A-1221 Vienna, Avstrija
Industriestrasse 67, 1221 Vienna, Austria
Industriestrasse 67, 1221 Dunaj, Avstrija
Ineligible
Neprimerni
INFAI, Institut für biomedizinische Analytik & NMR-Imaging GmbH Universitätsstr.
INFAI, Institut für biomedizinische Analytik & NMR Imaging GmbH Universitätsstr.
INFAI, Institut für biomedizinische Analytik & NMR-Imaging GmbH Universitätsstraße 142
INFAI, Institut für biomedizinische Analytik & NMR-Imagaing GmbH Universitätsstraße 142
Infanrix hexa can be given concomitantly with pneumococcal conjugate vaccine (PCV7, PCV10 and PCV13), meningococcal serogroup C conjugate vaccine (CRM197 and TT conjugates), meningococcal serogroups A, C, W-135 and Y conjugate vaccine (TT conjugate), oral rotavirus vaccine and measles- mumps-rubella-varicella (MMRV) vaccine.
Cepivo Infanrix hexa se lahko uporablja sočasno s konjugiranim pnevmokoknim cepivom (PCV7, PCV10 in PCV13), konjugiranim cepivom proti meningokokom serološke skupine C (konjugati CRM 197 in TT), konjugiranim cepivom proti meningokokom seroloških skupin A, C, W-135 in Y (konjugat TT), peroralnim cepivom proti rotavirusom in cepivom MMRV (cepivo proti ošpicam- mumpsu-rdečkam-noricam).
Infanrix hexa can be given to infants who received a hepatitis B vaccine at birth.
Cepivo Infanrix hexa se lahko da dojenčkom, ki so bili ob rojstvu cepljeni proti hepatitisu B.
Infanrix hexa contains neomycin and polymyxin
Cepivo Infanrix hexa vsebuje neomicin in polimiksin
Infanrix hexa contains small amounts of:
Cepivo Infanrix hexa vsebuje majhne količine:
Infanrix hexa helps your child’s body make its own protection (antibodies).
Cepivo Infanrix Hexa pomaga telesu vašega otroka ustvariti lastno zaščito (protitelesa).
Infanrix hexa is a combination of components that have been available in the European Union (EU) in other vaccines: diphtheria, tetanus, pertussis and hepatitis B were available in Infanrix HepB from 1997 until 2005, and diphtheria, tetanus, pertussis, polioviruses and the Hib component are available in other vaccines.
Cepivo Infanrix hexa je kombinacija sestavin, ki so v Evropski uniji (EU) na voljo v drugih cepivih: davica, tetanus, oslovski kašelj in hepatitis B so bili na voljo v cepivu Infanrix HepB od leta 1997 do 2005, davica, tetanus, oslovski kašelj, poliovirusi in sestavina Hib pa so na voljo v drugih cepivih.
Infanrix hexa is a vaccine, which is available as a powder and suspension that are made up into a suspension for injection.
Infanrix hexa je cepivo, ki je na voljo kot prašek in suspenzija za pripravo suspenzije za injiciranje.
Infanrix hexa is a vaccine.
Infanrix hexa je cepivo.
Infanrix hexa is available in packs of 1 and 50.
Cepivo Infanrix hexa je na voljo v pakiranjih po 1 in 50.
Infanrix hexa is available in packs of 1, 10, 20 and 50 with or without needles, and a multipack of 5 packs, each containing 10 vials and 10 pre-filled syringes, without needles.
Cepivo Infanrix hexa je na voljo v pakiranjih po 1, 10, 20 in 50 napolnjenih injekcijskih brizg s priloženimi injekcijskimi iglami ali brez njih in pakiranje, ki vsebuje 5 posameznih pakiranj z 10 vialami in 10 napolnjenimi injekcijskimi brizgami brez igel.
Infanrix hexa is contraindicated if the infant has experienced an encephalopathy of unknown aetiology, occurring within 7 days following previous vaccination with pertussis containing vaccine.
Uporaba cepiva Infanrix hexa je kontraindicirana, če je otrok prebolel encefalopatijo neznanega vzroka, ki se je pojavila v sedmih dneh po predhodnem cepljenju s cepivom, ki je vsebovalo tudi komponento proti oslovskemu kašlju.
Infanrix hexa is given by deep injection into a muscle.
Cepivo Infanrix hexa se daje z globoko injekcijo v mišico.
Infanrix hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b.
Cepivo Infanrix hexa je indicirano za osnovno in obnovitveno cepljenje otrok proti davici, tetanusu, oslovskemu kašlju, hepatitisu B, otroški ohromelosti in boleznim, ki jih povzroča Haemophilus influenzae tipa b.
Infanrix hexa is used to protect infants under three years of age against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis (polio) and diseases caused by Hib (such as bacterial meningitis).
Cepivo Infanrix hexa se uporablja za zaščito otrok, mlajših od treh let, proti davici, tetanusu, oslovskemu kašlju, hepatitisu B, otroški ohromelosti (polio) in boleznim, ki jih povzroča Hib (kot je bakterijski meningitis).
Infanrix hexa must not be used in infants who have had encephalopathy (brain disease) of unknown cause within seven days of receiving a vaccine containing pertussis components in the past.
Prav tako se ne sme uporabljati pri otrocih, ki so v preteklosti imeli encefalopatijo (obolenje možganov) neznanega vzroka v sedmih dneh po prejemu cepiva, ki je vsebovalo komponente oslovskega kašlja.
Infanrix hexa or any of the ingredients of the vaccine (listed in section 6).
če je alergičen na: cepivo Infanrix hexa ali katero koli sestavino tega cepiva (navedeno v poglavju 6);
Infanrix hexa or any of the ingredients of this vaccine (listed in section 6).
če je alergičen na: cepivo Infanrix hexa ali katero koli sestavino tega cepiva (navedeno v poglavju 6);
Infanrix hexa should be postponed in infants with a severe sudden fever.
Pri otrocih, ki imajo nenadno visoko telesno temperaturo, je treba cepljenje s cepivom Infanrix hexa odložiti.
Infanrix hexa should not be given if any of the above applies to your child.
Če karkoli od navedenega velja za vašega otroka, ne sme prejeti cepiva Infanrix hexa.
Infanrix hexa should not be used in infants who may be hypersensitive (allergic) to any of the active substances, to any of the other ingredients of the vaccine, or to neomycin and polymyxin (antibiotics).
Zdravila Infanrix hexa ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) katero koli od zdravilnih učinkovin, katero koli od drugih sestavin zdravila ali polimiksin (antibiotik).
Infanrix hexa will be given as an injection into a muscle.
Cepivo Infanrix hexa bo zdravnik dal v obliki injekcije v mišico.
Infanrix hexa will be given as an injection into a muscle.
Cepivo Infanrix hexa vam bo zdravnik dal v obliki injekcije v mišico.
Infanrix hexa will not prevent disease caused by pathogens other than Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, hepatitis B virus, poliovirus or Haemophilus influenzae type b.
Cepivo Infanrix hexa ne prepreči bolezni, ki jih povzročijo drugi patogeni, ne pa Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, virus hepatitisa B, poliovirus ali Haemophilus influenzae tipa b.
Infanrix hexa, Powder and suspension for suspension for injection
Infanrix hexa – prašek in suspenzija za suspenzijo za injiciranje
Infanrix hexa, Powder and suspension for suspension for injection
Infanrix hexa, prašek in suspenzija za suspenzijo za injiciranje
Infanrix hexa, Powder and suspension for suspension for injection in a pre-filled syringe Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed)
Infanrix hexa – prašek in suspenzija za suspenzijo za injiciranje v napolnjeni injekcijski brizgi Adsorbirano cepivo proti davici (D), tetanusu (T), oslovskemu kašlju (brezcelično, pripravljeno iz antigenskih sestavin) (Pa), hepatitisu B (rekombinantno) (HBV), otroški ohromelosti (inaktivirano) (IPV) in hemofilusu influence tipa b (konjugirano) (Hib)
Infanrix hexa, Powder and suspension for suspension for injection in a pre-filled syringe Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed).
Infanrix hexa, prašek in suspenzija za suspenzijo za injiciranje v napolnjeni injekcijski brizgi Adsorbirano cepivo proti davici (D), tetanusu (T), oslovskemu kašlju (brezcelično, pripravljeno iz antigenskih sestavin) (Pa), hepatitisu B (rekombinantno) (HBV), otroški ohromelosti (inaktivirano) (IPV) in hemofilusu influence tipa b (konjugirano) (Hib).
Infanrix Penta can be considered for the booster if the composition is in accordance with the official recommendations.
Cepivo Infanrix Penta se lahko uporabi za obnovitveno cepljenje, če njegova sestava ustreza uradnim priporočilom.
Infanrix Penta helps your child’s body make its own protection (antibodies).
Cepivo Infanrix Penta pomaga telesu vašega otroka ustvariti lastno zaščito (protitelesa).
Infanrix Penta is a combination of components that have been available in the European Union (EU) in other vaccines: diphtheria, tetanus, pertussis and hepatitis B were available in Infanrix HepB from 1997 until 2005, and diphtheria, tetanus, pertussis and polioviruses are available in other vaccines.
Cepivo Infanrix Penta je kombinacija sestavin, ki so v Evropski uniji (EU) na voljo v drugih cepivih: komponente davice, tetanusa, oslovskega kašlja in hepatitisa B so bili na voljo v cepivu Infanrix HepB od leta 1997 do 2005, komponente davice, tetanusa, oslovskega kašlja in poliovirusi pa so na voljo v drugih cepivih.
Infanrix Penta is a white, slightly milky liquid presented in a pre-filled syringe (0.5 ml).
Cepivo Infanrix Penta je bela, rahlo mlečna tekočina in je na voljo v napolnjeni injekcijski brizgi (0,5 ml).
Infanrix Penta is available in packs of 1, 10, 20 and 50 with or without needles.
Cepivo Infanrix Penta je na voljo v pakiranjih po 1, 10, 20 in 50 injekcijskih brizg z injekcijskimi iglami ali brez njih.
Infanrix Penta should be postponed in infants with a severe sudden fever.
Pri otrocih, ki imajo nenadno povišano telesno temperaturo, je treba cepljenje s cepivom Infanrix Penta odložiti.
Infanrix Penta should not be given if any of the above apply to your child.
Če karkoli od navedenega velja za vašega otroka, ne sme prejeti cepiva Infanrix Penta.
Infanrix Penta Suspension for injection DTPa-HBV-IPV
Infanrix Penta Suspenzija za injiciranje DTPa-HBV-IPV
Infanrix Penta will be given as an injection into a muscle.
Cepivo Infanrix Penta bo zdravnik dal v obliki injekcije v mišico.
Infanrix Penta, or any ingredients in Infanrix Penta (listed in Section 6) neomycin or polymyxin (antibiotics).
je alergičen (preobčutljiv) na: cepivo Infanrix Penta ali katerokoli sestavino cepiva Infanrix Penta (navedene v poglavju 6); neomicin ali polimiksin (antibiotika).
Infanrix Penta, Suspension for injection
Infanrix Penta – suspenzija za injiciranje
Infantile- and Late- onset Pompe disease
Zgodnji in pozni nastop Pompejeve bolezni
Infantile-onset Pompe disease
Zgodnji nastop Pompejeve bolezni
Infantile-onset Pompe disease; clinical trial in patients aged 6 months to 3.5 years
Zgodnji nastop Pompejeve bolezni; klinično preskušanje pri bolnikih starih od 6 mesecev do 3,5 let.
Infants 0 – 12 months of age
Dojenčki, stari od 0 do 12 mesecev
Infants 2 months to 5 months of age
Dojenčki, stari od 2 do 5 mesecev
Infants 6 months to 11 months of age
Dojenčki, stari od 6 do 11 mesecev
Infants 6 to 23 months, children and adolescents weighing less than 50 kg
Dojenčki od 6. do 23. meseca, otroci in mladostniki s telesno maso manj kot 50 kg
Infants 6-11 months
Dojenčki 6-11 mesecev
Infants age 2 - 6 months: the primary infant series consists of three doses, each of 0.5 ml, the first dose usually given at 2 months of age and with an interval of at least 1 month between doses.
Dojenčki od 2. do 6. meseca starosti: primarno zaporedje za dojenčke sestavljajo trije odmerki po 0,5 ml; prvi odmerek damo običajno pri 2 mesecih starosti; med naslednjima odmerkoma mora biti najmanj enomesečni presledek.
Infants aged 6 weeks-6 months
Dojenčki, stari od 6 tednov do 6 mesecev
Infants aged 7 - 11 months: two doses, each of 0.5 ml, with an interval of at least 1 month between doses.
Dojenčki, stari od 7 do 11 mesecev: dva odmerka po 0,5 ml; med obema odmerkoma mora biti vsaj enomesečni presledek.
Infants aged 7 to- 11 months should receive two injections.
Dojenčki, stari od 7 do 11 mesecev, morajo prejeti dva odmerka cepiva.
infants aged 7-11 months: The vaccination schedule consists of two primary doses of 0.5 ml with an interval of at least 1 month between doses.
Dojenčki, stari od 7 do 11 mesecev: Shema cepljenja mora obsegati 2 primarna odmerka po 0,5 ml z vsaj 1-mesečnim presledkom med odmerkoma.
Infants aged between seven and 11 months are given two doses with an interval of at least one month between them.
Dojenčki, stari od sedem do 11 mesecev, potrebujejo dva odmerka, med katerima mora biti vsaj enomesečni presledek.
Infants aged between seven and 11 months need two doses, with an interval of at least one month between doses.
Dojenčki, ki so stari od sedem do 11 mesecev, potrebujejo dva odmerka, med katerima mora biti vsaj enomesečni presledek.
Infants aged between six weeks and six months are given three doses with an interval of at least one month between each dose, with the first dose usually given at two months of age.
Dojenčkom, starim od šest tednov do šest mesecev, se dajo trije odmerki z vsaj enomesečnim presledkom med posameznimi odmerki, prvi odmerek pa se navadno da pri starosti dveh mesecev.
Infants aged between two and six months need three doses.
Dojenčki, stari od dva do šest mesecev, potrebujejo tri odmerke.
Infants and children (up to 10 years of age)
Dojenčki in otroci (stari do 10 let)
Infants and children aged 6 to 35 months:
Dojenčki in otroci, stari od 6 do 35 mesecev:
Infants and children aged 6–35 months
Dojenčki in otroci, stari od 6 do 35 mesecev
Infants and toddlers 4 weeks to less than 2 years of age
Dojenčki in malčki, stari od 4 tedne do manj kot 2 leti
Infants and Toddlers from the age of 4 weeks
Dojenčki in malčki, starejši od 4 tednov
infants given any other medicinal products, notably those mentioned below. infants breastfed by mothers taking any other medicinal products, notably those mentioned below.
dojenčki, ki prejemajo kakršna koli druga zdravila, predvsem spodaj omenjena. dojeni dojenčki, katerih matere jemljejo kakršna koli druga zdravila, predvsem spodaj omenjena.
Infants less than 1 year
Dojenčki mlajši od 1 leta
Infants less than 1 year
Dojenčki stari manj kot 1 leto
Infants less than 1 year
Dojenčki, mlajši od 1 leta
Infants less than 1 year (0 to 12 months)
Dojenčki mlajši od 1 leta (0 do 12 mesecev)
Infants less than 1 year (including full term new born babies):
Dojenčki, stari manj kot 1 leto (vključno z donošenimi novorojenčki):
Infants less than 1 year (including full term newborn babies)
Dojenčki, stari manj kot 1 leto (vključno z donošenimi novorojenčki)
Infants less than 1 year (including full-term newborn babies)
Dojenčki mlajši od 1 leta (vključno z donošenimi novorojenčki)
Infants less than 1 year (including full-term newborn babies)
Dojenčki mlajši od 1 leto (vključno z donošenimi novorojenčki)
Infants less than 1 year (including full-term newborn babies)
Dojenčki, stari manj kot 1 leto (vključno z donošenimi novorojenčki)
Infants less than 1 year (including full-term newborn babies):
Dojenčki mlajši od 1 leta (vključno z donošenimi novorojenčki):
Infants less than 1 year of age: The pharmacokinetics, pharmacodynamics and safety of oseltamivir have been evaluated in two uncontrolled open-label studies including influenza infected children less than one year of age (n=135).
Dojenčki stari manj kot 1 leto: farmakokinetika, farmakodinamika in varnost oseltamivirja je bila ovrednotena v dveh odprtih kliničnih študijah brez kontrolne skupine, ki sta vključevali z gripo okužene otroke, mlajše od 1 leta (n = 135).